



ASX & Media Release

## Publication on Positive Response to PAT-SM6 in Combination Therapy for Multiple Myeloma

- **Publication of previously-reported positive response of Multiple Myeloma (MM) patient treated with PAT-SM6 and other agents**

**Melbourne, Australia; April 5, 2016:** Patrys Limited (**ASX: PAB**) is pleased to announce the publication of a new scientific article in the journal *Clinical Cancer Research* (CCR) regarding its IgM therapeutic candidate PAT-SM6. The article reports on the positive response of a patient to PAT-SM6 in combination with other marketed multiple myeloma drugs. The clinical results for this patient were first disclosed by Patrys on May 28, 2014. The CCR article is currently available online and will be included in a future print edition of the journal.

The paper, which combines cell and clinical studies, describes the clinical progression of MM and the issues associated with resistance to currently approved therapies. Of particular relevance was the observation that levels of surface glucose-regulated protein 78 (sGRP78) increased in drug resistant and late-stage MM disease. As PAT-SM6 binds to GRP78 collaborating clinicians believed that it would be a potent agent to combine with existing therapies. The combination of PAT-SM6, bortezomib and lenalidomide was tested in a multi-drug resistant MM patient who responded positively, with partial remission of both intra- and extramedullary lesions.

“Patrys believes that IgM antibodies have a valuable role to play in the treatment of a range of cancers, and this clinical experience supports this view” said Dr James Campbell, CEO and Managing Director of Patrys. “At this time, additional clinical investigation with PAT-SM6 remains on hold until process development and manufacturing optimisation can be achieved - potentially through strategic partnerships.”

A link to the article is available at;

<https://clincancerres.aacrjournals.org/content/early/2016/03/30/1078-0432.CCR-15-3111.abstract>

**-Ends-**

**For further information, please contact:**

*Patrys Limited:*  
James Campbell  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

*Patrys IR:*  
Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

*Patrys Media:*  
Kellie Stanborough  
Buchan Consulting  
P: +61 3 9866 4722  
[kstanborough@buchanwe.com.au](mailto:kstanborough@buchanwe.com.au)



**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).

**About PAT-SM6:**

PAT-SM6 is a natural human IgM antibody which has been shown to have potent anti-cancer properties in a large number of pre-clinical studies. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target and the mechanism of action and has patents granted in various jurisdictions including Australia, United States, Europe, Japan and the United Kingdom. PAT-SM6 has shown evidence of potential therapeutic benefit in a Phase I/IIa clinical trial in patients with relapsed and refractory multiple myeloma and has been granted orphan drug status in Europe and the USA for multiple myeloma.

**About Multiple Myeloma:**

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, and new therapies are desperately needed to treat patients who become resistant to established chemotherapeutics. There is an estimated 220,000 cases worldwide and the incidence is increasing. The five-year survival of patients is approximately 30% (at 10 years ~20%). Despite new marketed therapies, multiple myeloma remains largely incurable and fatal. The multiple myeloma market is dominated by three major products: Revlimid, Velcade and Kyprolis (Carfilzomib) with combined net sales greater than US\$8 Billion in 2013. In 2015 monoclonal antibodies Efficacy (Elotuzumab) and Darzalex (Daratumumab) were approved by the FDA for the treatment of multiple myeloma.